Last reviewed · How we verify
AGT-181
At a glance
| Generic name | AGT-181 |
|---|---|
| Also known as | HIRMAb-IDUA, fusion protein of monoclonal antibody to human insulin receptor fused to alpha-L-iduronidase |
| Sponsor | ArmaGen, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I (PHASE1, PHASE2)
- Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I (PHASE1, PHASE2)
- Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I (PHASE1)
- Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |